Valuation: Kadimastem

Market Cap 52.51M 0 17.57M 15.05M 14.08M 12.89M 24.19M 1.68B 24.51M 166M 64.87M 844M 65.96M 64.52M 2.79B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 52.51M 0 17.57M 15.05M 14.08M 12.89M 24.19M 1.68B 24.51M 166M 64.87M 844M 65.96M 64.52M 2.79B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
31.94%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-8.93% - - 17.57M
+1.09%+5.26%+4.44%+26.03% 51.61B
-1.07%+2.82%+474.18%+601.24% 44.89B
+1.47%+9.79%+40.15%+21.21% 42.77B
+1.44%+7.77%+19.27%+90.94% 42.58B
-0.93%-4.33%+17.87%+51.96% 31.82B
+1.32%+7.30%+36.93%+152.36% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.28%+5.41%+91.01%+46.93% 14.09B
Average +0.40%+4.43%+86.37%+128.27% 30.72B
Weighted average by Cap. +0.49%+4.72%+102.57%+148.52%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Kadimastem
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Employees
11